The purpose of the current study is to assess the effectiveness of protein-based COVID-19 or influenza vaccines when given individually or together via oral/ sublingual mucosal route instead of intramuscular delivery. The comparator will be a seasonal influenza vaccine which will also be administered with Advax-CpG adjuvant via the oral route. This study will use a cross-over design and everyone in the study will over a space of about 4 months receive both the COVID-19 and influenza vaccines.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
SARS-CoV-2 Seroconversion
Timeframe: Between baseline and 2 weeks post the second dose
Influenza Seroconversion
Timeframe: Between baseline and 2 weeks post the second dose
SARS-CoV-2 Seroprotection
Timeframe: Between baseline and 2 weeks post the second dose
Influenza Seroprotection
Timeframe: Between baseline and 2 weeks post the second dose
SARS-CoV-2 Geometric mean titer fold change
Timeframe: Between baseline and 2 weeks post the second dose
Influenza geometric mean titer fold change
Timeframe: Between baseline and 2 weeks post the second dose
Safety assessment 1
Timeframe: Between time of administration of first dose and through study completion, an average of 10 months
Safety assessment 2
Timeframe: Between time of administration of first dose and through study completion, an average of 10 months
SARS-CoV-2 infection
Timeframe: From 2 weeks post the administration of the second dose and through study completion, an average of 10 months
Influenza infection
Timeframe: From 2 weeks post the administration of the second dose and through study completion, an average of 10 months